Avalo Therapeutics
AVTX
36 hedge funds and large institutions have $88.3M invested in Avalo Therapeutics in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 7 closing their positions.
248% more capital inflows, than outflows
Capital inflows: $11.1M | Capital outflows: $3.2M
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
3.37% more ownership
Funds ownership: 57.46% → 60.83% (+3.4%)
0% more funds holding
Funds holding: 36 → 36 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$8.74M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$692K |
| 3 |
Millennium Management
New York
|
+$357K |
| 4 |
Boothbay Fund Management
New York
|
+$335K |
| 5 |
State Street
Boston,
Massachusetts
|
+$223K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.48M |
| 2 |
EAM Investors
Solana Beach,
California
|
-$605K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$469K |
| 4 |
Atom Investors
Austin,
Texas
|
-$220K |
| 5 |
Renaissance Technologies
New York
|
-$181K |
AVTX Hedge Fund Activity: Q3 2019 in Review
36 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2019, worth a combined $88.3M — down 34% from $133M a quarter earlier.
Fund positioning in AVTX was balanced in Q3 2019: 7 funds opened new positions, 7 closed out, 10 added to existing stakes and 7 trimmed.
The largest buyer was Armistice Capital, adding an estimated $8.74M. The largest seller was Assenagon Asset Management, exiting entirely with an estimated $1.48M sold.
- 36 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $88.3M of Avalo Therapeutics stock for Q3 2019, down 34% quarter-over-quarter.
- 7 funds opened new Avalo Therapeutics positions in Q3 2019 and 7 closed out, a net change of 0 holders.
- The largest Avalo Therapeutics buyer in Q3 2019 was Armistice Capital, an estimated $8.74M added.
- The largest Avalo Therapeutics seller in Q3 2019 was Assenagon Asset Management, an estimated $1.48M sold.
Based on aggregated 13F filings for Q3 2019.